Inhibition of neurogenic inflammation in abortive migraine treatment
- 65 Downloads
Neurogenic inflammation is mediated through the release of peptides, called neuropeptides, from the sensory nerve fibers involved in nociception. It comprises two processes, plasma-protein extravasation and neurogenic vasodilation, mediated predominantly by substance P and calcitonin gene-related peptide, respectively. Substance P is released from the unmyelinated C fibers and opens up post-capillary venules by acting on neurokinin-1 receptors, allowing the extravasation of plasma proteins. Calcitonin gene-related peptide, on the other hand, is released from the small myelinated Aθ fibers and dilates the arterioles by stimulating receptors of its own.
KeywordsDura Mater Trigeminal Ganglion Cortical Spreading Depression Neurogenic Inflammation Headache Relief
Unable to display preview. Download preview PDF.
- 5.Earl NL, McDonald SA, Lowy MT (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine (abstract). Cephalalgia 19: 357Google Scholar
- 6.Manilla BG, Cutler N, Leibowitz MT et al (2001) Safety and efficacy of PNU-142633 a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia; in press Google Scholar
- 9.Goldstein DJ, Roon KI, Offen WW et al (1999) Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370 (abstract). Cephalalgia 19: 318Google Scholar
- 19.Moussaoui SM, Garret C (1997) Are substance P antagonists potential treatment for migraine and related headaches, pain, and emesis? In: J Olesen, P Tfelt-Hansen (eds): Headache treatment: trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia, 303–311Google Scholar
- 24.Norman B, Panebianco D, Block GA (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine (abstract). Cephalalgia 18: 407Google Scholar
- 26.Connor HE, Bertin L, Gillies S et al (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine (abstract). Cephalalgia 18: 392Google Scholar
- 28.Goldstein DJ, Offen WW, Klein EG, Phebus LA (1999) Lanepitant, an NK-1 antagonist, in migraine prophylaxis (abstract). Cephalalgia 19: 377Google Scholar